|
Indian Pediatr 2015;52: 697-700 |
 |
Daily Versus Single Dose Vitamin D
Therapy in Children and Adolescents: How Good is the Evidence?
|
Source Citation: Tan JKG, Kearns P, Martin AC, Siafarikas A.
Randomised controlled trial of daily versus stoss vitamin D therapy in
Aboriginal children. J Paediatr Child Health. 2015;51:626-31.
Section Editor: Abhijeet Saha
|
Summary
In this randomized controlled trial (RCT), 43
participants having 25(OH) D level less than 78 nmol/L received daily or
stoss vitamin D therapy with follow-up at 4–6 months and 9–12 months. Of
these, 34 (79%) had insufficient (50–78 nmol/L) levels, 8 (19%) had
mildly deficient (27.5–50 nmol/L) levels and 1 (2%) had deficient (<27.5
nmol/L) vitamin D level. Daily vitamin D therapy had a higher average
increase in 25(OH) D levels from baseline than stoss therapy; however,
this was not significant. The authors concluded that vitamin D
insufficiency is common in Aboriginal children of Western Australia and
stoss therapy is a safe alternative to daily vitamin D therapy, but
requires further evaluation of timing and doses.
Commentaries
Evidence-based Medicine Viewpoint
Relevance: Recent years have witnessed an
unprecedented interest in vitamin D status and potential impact of
deficiency/insufficiency in health and various disease states. Initial
studies focused on documenting population levels and establishing the
proportion of people with levels below the conventional definitions of
deficiency/insufficiency. Later investigations identified associations
with various disease conditions including public health problems such as
childhood pneumonia and iron deficiency anemia. More recently,
investigations have focused on clinical benefits of therapeutic
supplementation with vitamin D. These pieces of research have spawned
further research in three different directions viz (i)
focused investigations to identify plausible biologic mechanisms for
pathologic effects of vitamin D deficiency; (ii) confirmation of
therapeutic benefit of vitamin D supplementation in various clinical
conditions; and (iii) replication of measurement of vitamin D
levels in various population subgroups. A considerable body of recent
research from India – both in children as well as adults – is also
oriented in these directions [1-10]. These investigations are pertinent
because despite the presence of abundant sunshine in India, high
prevalence of vitamin D deficiency/insufficiency is reported [11,12].
Against this background, the recent publication of a randomized
controlled trial (RCT) conducted in Australian aboriginal children [13]
provides an opportunity for a re-look at vitamin D related research.
Critical appraisal: The study [13] was
initiated with a three-fold objective viz (i) reporting
the status of vitamin D in Australian aboriginal children; (ii)
comparison of vitamin D level among those residing in rural vs
urban areas; and (iii) evaluating the efficacy of daily vitamin D
supplementation vs stoss therapy in those with low levels. Stoss
therapy refers to single high dose oral administration of vitamin D.
Such a regimen is expected to reduce costs and improve compliance in
comparison to daily administration of a similar total dose [14]. The
investigators chose to conduct the study in aboriginal children
anticipating greater risk of deficiency in them (on account of higher
melanin content in skin). Accordingly, they enrolled aboriginal children
and adolescents (<16 y) who were admitted in two health-care settings
(representing rural and urban areas). The authors clearly reported the
latitude of the geographic location of the two sites; unfortunately
these differed by over 14 degrees raising the possibility of a
completely different pattern of sun exposure. It is unclear why such an
obvious confounding factor was overlooked.
The investigators failed to calculate the appropriate
sample size required for their first two objectives. Instead, they
merely stated that 40 children would be required for detecting a
statistically significant difference in vitamin D level in the two
therapeutic arms (daily therapy vs stoss therapy). Interestingly,
even this limited sample size was not achieved even at the start of the
therapy component of this study.
Methodology for the first two objectives has not been
described. It is unclear whether consecutive children were enrolled, or
a sampling framework to minimize selection bias was applied. Similarly,
there was no effort to ensure matching of children enrolled from the
rural and urban areas. These glaring omissions create serious risk of
bias compromising the validity of the study. It almost appears as though
the investigators were unconcerned about the first two objectives of the
study. The third objective was approached through a RCT; wherein a
computer was used to generate a block randomization sequence. Sealed
envelopes were also used, although they were white (perhaps not opaque);
hence the adequacy of allocation concealment cannot be judged. There was
no blinding of participants; further, it appears that even the
laboratory personnel testing the samples were unblinded. These also
raise the risk of bias in this component of the study.
The authors stated that their primary outcome was
vitamin D level at three points viz baseline, 4-6 months, and
8-12 months after initiating therapy. Unfortunately it is unclear which
time-point was used to calculate the sample size. Further these time
points are presented somewhat differently in the flow diagram (6 weeks,
6 months, 12 months) and in the ‘Discussion’ section (4-8 months and
8-12 months). Strangely, these discrepancies have been missed by the
authors as well as the review/editorial process.
On the plus side, the definitions of vitamin D
deficiency (<50 nmol/L equivalent to 20 ng/ml) and insufficiency (50-78
nmol/L equivalent to 20-31.2 ng/mL) conform to generally accepted
standards. In contrast, the dosage of vitamin D chosen for stoss therapy
in this trial (100,000 U) is lower than that used in other studies; the
reason for this has not been described. However, children with severe
deficiency (vitamin D less than 27.5 nmol/L or 11 ng/mL) received twice
the dose as those with levels between 27.5 and 78 nmol/L.
Among 304 potentially eligible children, only 73 were
evaluated for 25(OH) D levels. Of the 231 excluded children, 23 (10%)
missed recruitment (no specific reason given). Of 43 children eligible
to enter the RCT, only 37 were actually enrolled (thus the sample size
was not achieved). Among these 37, only 6 were available for the final
outcome measurement. This significant selection and attrition bias
further compromises validity.
Although the serious threats to validity make it
inappropriate to explore the results, these are briefly described for
academic purposes. Overall, almost 60% of the children were found to
have low vitamin D levels despite relatively high skin phototype (median
score 5 in a scale where the highest is 6). It may be speculated that
this is more-or-less as would be expected. Children from the rural area
had higher vitamin D level, although the small sample size (only 12 in
the rural group) makes it difficult to be confident of this
interpretation. Although samples sizes are very small, it appears that
vitamin D level did not vary by skin phototype. As mentioned, only 37 of
43 eligible participants were randomized to daily or stoss vitamin D
therapy; of these, only 16 and 6 were available for the first and second
follow-up measurements. The reasons for failure to randomize all
eligible children, and follow them up per protocol have not been
described. In the limited cohort available, it appears that daily
therapy resulted in a higher mean increase in vitamin D levels.
The authors of this RCT recognized and acknowledged
some of the limitations described above. Despite these limitations, and
their own observation suggesting daily therapy yielded higher increase
in vitamin D, they suggest that stoss therapy could be a useful option
to treat vitamin D deficiency/insufficiency. It must be emphasized that
such an interpretation from the methodology used and data available, is
inappropriate, and at high risk of bias.
Extendibility: The serious limitations in
the execution and outcomes of this study preclude an exploration of
generalizability of results. Despite this, some lessons can be learnt
for the Indian setting, especially as 25 (OH) D measurement is
relatively easy and affordable in most research settings. Investigators
must resist the temptation of undertaking a poorly planned study
measuring 25 (OH) D levels in cohorts of children/adults (healthy or
otherwise). When such studies are already available, their results must
be interpreted with caution. Further, India is a geographically and
ethnically diverse country; hence exposure to sunlight, UV index,
population phototypes, etc can differ markedly even in
populations/regions appearing to have common parameters. This makes
extrapolation of results from one setting to other settings somewhat
complicated. Last but not the least, there is ample data suggesting that
the majority of people (healthy state or with various diseases) have low
vitamin D levels (as per the conventional definitions). Therefore,
further research must focus on biologic implications of this, and/or
management strategies – rather than merely confirming/replicating
existing data.
Conclusions: This study highlights several
deficiencies in terms of research methodology and data interpretation.
No applicable conclusions can be confidently drawn for our setting.
References
1. Ponnarmeni S, Kumar AS, Singhi S, Bansal A, Dayal
D, Kaur R, et al. Vitamin D deficiency in critically ill children
with sepsis. Paediatr Int Child Health. 2015: 2046905515Y0000000042. [Epub
ahead of print]
2. Sharma S, Jain R, Dabla PK. The role of 25-hydroxy
vitamin D deficiency in iron deficient children of North India. Indian J
Clin Biochem. 2015;30:313-7.
3. Basu S, Gupta R, Mitra M, Ghosh A. Prevalence of
vitamin D deficiency in a pediatric hospital of eastern India. Indian J
Clin Biochem. 2015;30:167-73.
4. Kumar P, Shenoi A, Kumar RK, Girish SV, Subbaiah
S. Vitamin D deficiency among women in labor and cord blood of newborns.
Indian Pediatr. 2015;52:530-1.
5. Bachhel R, Singh NR, Sidhu JS. Prevalence of
vitamin D deficiency in north-west Punjab population: A cross-sectional
study. Int J Appl Basic Med Res. 2015;5:7-11.
6. Sharma R, Saigal R, Goyal L, Mital P, Yadav RN,
Meena PD, et al. Estimation of vitamin D levels in rheumatoid
arthritis patients and its correlation with the disease activity. J
Assoc Physicians India. 2014;62:678-81.
7. Roy A, Lakshmy R, Tarik M, Tandon N, Reddy KS,
Prabhakaran D. Independent association of severe vitamin D deficiency as
a risk of acute myocardial infarction in Indians. Indian Heart J.
2015;67:27-32.
8. Prasad S, Raj D, Warsi S, Chowdhary S. Vitamin D
deficiency and critical illness. Indian J Pediatr. 2015 May 14. [Epub
ahead of print].
9. Choudhary N, Gupta P. Vitamin D supplementation
for severe pneumonia – A randomized controlled trial. Indian Pediatr.
2012;49:449-54.
10. Das RR, Singh M, Panigrahi I, Naik SS. Vitamin D
supplementation for the treatment of acute childhood pneumonia: A
systematic review. ISRN Pediatr. 19; 2013:459160.
11. Ritu G, Gupta A. Fortification of foods with
vitamin d in India: Strategies targeted at children. J Am Coll Nutr.
2015;34:263-72.
12. Balasubramanian S, Dhanalakshmi K, Amperayani S.
Vitamin D deficiency in childhood – A review of current guidelines on
diagnosis and management. Indian Pediatr. 2013;50:669-75.
13. Tan JK, Kearns P, Martin AC, Siafarikas A.
Randomised controlled trial of daily vs stoss vit D therapy in
Aboriginal children. J Paediatr Child Health. 2015;51:626-31.
14. Priyambada L, Bhatia V, Singh N, Bhatia E. Serum
25 hydroxyvitamin D profile after single large oral doses of
cholecalciferol (vitamin D3) in medical staff in North India:Aa pilot
study. J Postgrad Med. 2014;60:52-6.
Joseph L Mathew
Department of Pediatrics,
PGIMER, Chandigarh, India.
Email:
[email protected]
Nutritionist’s Viewpoint
As the number of related articles that have been
submitted to Indian Pediatrics attest to, over the last two decades
vitamin D physiology, its actions and role in disease have become the
flavors of the month in many parts of the world, resulting in vitamin D
status being assessed in numerous different groups, communities and
populations. In a number of these, rickets remains a public health
problem; thus an assessment of vitamin D status in these at-risk
communities might be warranted, but in the greater proportion of
communities, it is hard to understand why there should be concern about
vitamin D status at all. So it possibly is with the Aboriginal children
in Western Australia. I am sure the authors of the article would argue
that the experimental evidence showing vitamin D being involved in
numerous different functions and thus possibly affecting the well-being
of those with longstanding low vitamin D status, warrants determining
the vitamin D status of this group. But do we know what level of
25-hydroxyvitamin D [25(OH)D] constitutes vitamin D deficiency? I
certainly would be very cautious about using the cut-offs indicated by
the authors to diagnose vitamin D insufficiency or deficiency that
requires management, until we have much firmer prospective evidence that
children are at-risk when levels of 25-hydroxyvitamin D are between 30
and 50 nmol/L (12-20 ng/mL). I believe the recommendations made by the
Institute of Medicine [1] which indicate that the risk of clinical
vitamin D deficiency increases below 30 nmol/L, remain appropriate
currently. The authors of the current pilot study suggest that the
results obtained on the small number of children warrant the screening
of Aboriginal children attending hospitals and clinics, and that daily
supplements should be used for initial treatment; yet only 1 subject had
a 25(OH)D value of <27.5 nmol/L. From my perspective, the data presented
indicate that healthy Aboriginal children are not at risk of vitamin D
deficiency and therefore do not warrant screening.
One of the original aims of the study was to
determine the effectiveness of oral stoss therapy compared to daily
supplements in improving vitamin D status; however due to the small
number of children who returned for follow up, a meaningful comparison
could not be made. However, the study does raise two issues: (i)
when does one assess the effectiveness of stoss therapy in improving
vitamin D status, as serum 25(OH)D levels are not constant but rise and
then fall over several months; and (ii) how often should the
bolus of vitamin D be given and does the interval change depending on
the amount of vitamin D in the bolus and the size/age of the subject? In
a study conducted in healthy adult women, an oral bolus of vitamin D 3 (150,000
IU) resulted in a rise in 25(OH)D which peaked between days 7 and 14,
and had started to fall by day 28. Of interest was the change in serum
vitamin D levels themselves, which were maximal on day 1 and back to
baseline values by day 14 [2].
In conclusion, the study does not convince me to
change my current practice but it does raise questions about the
frequency and dosage required for stoss therapy. Until we have more
understanding of the changes in mineral and vitamin D homeostasis that
occur with stoss therapy, especially within the first two weeks of
dosing, I will continue where possible to use daily therapy to correct
vitamin D deficiency and to maintain sufficiency when necessary.
References
1. Institute of Medicine: Dietary Reference Intakes
for Calcium and Vitamin D. Washington DC: The National Academies Press,
2011.
2. Meekins ME, Oberhelman SS, Lee BR, Gardner BM, Cha
SS, Singh RJ, et al. Pharmacokinetics of daily versus monthly
vitamin D3 supplementation in non-lactating women. Eur J Clin Nutr.
2014;68:632-4.
John M Pettifor
Department of Pediatrics,
University of the Witwatersrand, Johannesburg,
South Africa
Email:
[email protected]
Pediatrician’s Viewpoint
Published under the category of ‘Original Article’ in
a peer-reviewed indexed journal with impact factor of 1.19, this study
is a classic example of misleading the science by posting conclusions
that are neither backed by a sound hypothesis nor derived from an
appropriate methodology. Authors conclude that vitamin D insufficiency
is common in Aboriginal children of Western Australia. One would be
surprised to know that this conclusion is drawn on the basis of an
opportunistic sample of only 78 children, arbitrarily picked from
hospitalized patients. The mean 25(OH)D level in study population was
74.5 nmol/L (95% CI 68.8,80.3), just a shade below the 78 nmol/L
cut-off, assumed for defining insufficiency. Authors have grossly
extrapolated these borderline results obtained on a cohort of sick
children (inpatients) to the entire Australian Aboriginal community.
This is unacceptable.
The study further, in a randomized controlled design,
compares daily vs. Stoss regimen in these vitamin D insufficient
children. The intervention is based on the premise that therapeutic
vitamin D supplementation is needed in all subjects with insufficient
vitamin D status, irrespective of whether they are symptomatic or not.
Bolus/long-term vitamin D supplementation was originally developed to
treat rickets (manifest vitamin D deficiency), but should it be used to
correct isolated biochemical deficiency, is still open to debate. It is
also to be noted that of 43 participants with low 25(OH)D levels (<78
nmol/L), who were given vitamin D therapy, only 9 were really deficient
[25(OH)D <50 nmol/L]. No specific mention is there to monitor for
hypercalcemia, hypercalciuria, pseudotumor cerebri, hypertension or
nephrolithiasis. Statistical analysis is also faulty, with parametric
tests used on a small sample size (without even testing for normality of
data). To add, the final comparison of outcome data is based on only 14
and 6 children at different times point. More than half were lost to
follow-up. Sufficient to say that the present study does not have any
value for translation into policy or recommendation for practice.
Piyush Gupta
Department of Pediatrics,
University College of Medical Sciences,
New Delhi, India.
Email:
[email protected]
|
|
 |
|